Modulation of CD4 cell cytokine production by colon cancer-associated mucin

Cancer Immunology Immunotherapy

Volumn 48, Issue 9, 1999, Pages 525-532

  Kim, Julian A ^a   Dayton, Mark A ^a   Aldrich, Wayne ^a   Triozzi, Pierre L ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

CD28; Costimulation; Interleukin 2; Macrophage inflammatory protein 1 ; T helper cells

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; MESSENGER RNA; MUCIN;

ARTICLE; CELL FUNCTION; CELL SECRETION; COLON CANCER; CYTOKINE PRODUCTION; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RECEPTOR BINDING;

EID: 0032716982     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050601     Document Type: Article

References (46)

1. 1. Adachi W, Sugenoya A, Iida F (1991) Immune competent cells of regional lymph nodes in colorectal cancer patients. I. Flow cytometric analysis of lymphocyte subpopulation. J Surg Oncol 46:110
2. 2. Agrawal B, Krantz MJ, Reddish MA, Longenecker BM (1998) Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 4:43
3. 3. Apostolopoulos V, Osinski C, McKenzie IFC (1998) MUC1 cross reactive ga1α (1, 3) gal antibodies in humans switch immune responses from cellular to humoral. Nature Med 4:315
4. 4. Barnd DL, Lan MS, Metzgar RS, Finn OJ (1989) Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 86:7159
5. 5. Berghella AM, Pellgrini P, Del Beato T, Marini M, Tomei E, Adorno D, Casciani CU (1998) The significance of an increase in soluble interluekin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from TH1 to TH2 and back. Cancer Immunol Immunother 45:241
6. 6. Bohmig GA, Kovarik J, Holter W, Pohanka E, Zlabinger GJ (1994) Specific down-regulation of proliferative T cell alloresponsiveness by interference with CD2/LFA-2 and LFA-1/ ICAM-1 in vitro. J Immunol 152:3720
7. 7. Bresalier RS, Niv Y, Byrd JC, Duh Qy, Toribara NW, Rockwell RW, Dahiya R, Kim YS (1991) Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis. J Clin Invest 87:1037
8. 8. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093
9. 9. Doran T, Stuhlmiller H, Kim JA, Martin EW, Triozzi PL (1997) Oncogene and cytokine expression of human colorectal tumors responding to immunotherapy. J Immunother 20:372
10. 10. Fearon E, Pardoll D, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Volgelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypass T helper function in the generation of an antitumor response. Cell 60:397
11. 11. Freeman GJ, Borriello F, Hodes RJ, Reiser H, Hathcock KS, Laszlo G, McKnight AJ, Kim J, Du L, Lombard DB, Gray GS, Nadler LM, Sharps AH (1993) Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 262:907
12. 12. Fung PYS, Longenecker BM (1991) Specific immunosuppressive activity of epiglycanin, a nucin-like glycoprotein secreted by a murine mammary adenocarcinoma TA3-HA). Cancer Res 51:1170
13. 13. Ghiotto-Ragueneau M, Battifora M, Truneh A, Waterfield MD, Olive D (1996) Comparison of CD28-B7.1 and B7.2 functional interaction in resting human T cells: phosphatidyl-inositol 3-kinase association to CD28 and cytokine production. Eur J Immunol 26:34
14. 14. Gillis S, Ferm MM, Ou W, Smith KA (1978) T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol 120:2027
15. 15. Green JB, Timmcke AE, Mitchell WT, Hicks TC, Gaithright B Jr, Ray JE (1993) Mucinous carcinoma - just another coon cancer? Dis Colon Rectum 36:49
16. 16. Greiner JW, Guadagni F, Goldstein D, Borden EC, Ritt RE, Witt P, LoBuglio AF, Saleh MN, and Schlom J (1991) Evidence for the elevation of serum carcinoembryonic antigen and tumor-associated glycoprotein-72 levels in patients administered interferons. Cancer Res 51:4155
17. 17. Guerder S, Carding SR, Flavell RA (1995) B7 costimulation is necessary for the activation of the lytic function in cytotoxic T lymphocyte precursors. J Immunol 155:5167
18. 18. Hathcock KS, Laszlo G, Dickler HB, Bradshaw J, Linsley P, Hodes RJ (1993) Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science 262:905
19. 19. Hayes DF, Siberstein DS, Rodrique SW, Kufe DW (1990) DF3 antigen, a human epithelial cell mucin inhibits adhesion of eosinophils to antibody-coated targets. J Immunol 145:962
20. 20. Ho JJ, Siddiki B, Kim YS (1995) Association of sialyl-Lewis (a) and sialyl-Lewis (x) with MUC-1 apomucin in a pancreatic cancer cell line. Cancer Res 55:3659
21. 21. Hodge JW, Abrams S, Schlom J, Kantor JA (1994) Induction of antitumor immunity by recombinant vaccina viruses expressing B7-1 and B72-2 costimulatory molecules. Cancer Res 54:5552
22. 22. Hollsberg P, Scholz C, Anderson DE, Greenfield EA, Kuchroo VK, Freeman GJ, Hafler DA (1997) Expression of a hypoglycosylated from of CD86 (B7-2) on human T cells with altered binding properties to CD28 and CTLA-4. J Immunol 159:4799
23. 23. Irani DN, Lin K-I, Griffin DE (1996) Brain-derived gangliosides regulate the cytokine production and proliferation of activated T cells. J Immunol 157:4333
24. 24. Jenkins MK, Taylor PS, Norton SD, Urdahl KB (1991) CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 147:2461
25. 25. Jerome KR, Barnd DL, Bendt KM, Boyer CM, Taylor-Papadimitriou J, McKenzie IFC, Bast R, Finn OJ (1991) Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule perferentially expressed by malignant cells. Cancer Res 51:2908
26. 26. Kim JA, Martin EW, Aldrich WA, Bender JA, Triozzi PL (1993) IL-2 production by T-helper lymphocytes is inhibited by soluble tumor-derived mucin via the CD28 pathway. Proc Am Assoc Cancer Res 34:450
27. 27. Lan MS, Hollingsworth MA, Metzgar RS (1990) Polypeptide core of a human pancreatic tumor mucin antigen. Cancer Res 50:2997-3001
28. 28. Laskin DL, Sirak AA, Robertson FM, Laskin JD (1991) Distinct patterns of chemotactic peptide-induced calcium mobilization in differentiated myeloid leukemia cells and peripheral blood neutrophils. J Leukoc Biol 49:369
29. 29. Linsley PS, Brady W, Grosmarie L, Aruffo A, Damle NK, Ledbetter JA (1991) Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin-2 mRNA accumulation. J Exp Med 173:721
30. 30. Linsley PS, Brady W, Urnes M, Grosmarie L, Damle NK, Ledbetter JA (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174:561
31. 31. Mueller DL, Jenkins MK, Chiodetti L, Schwartz RH (1990) An intracellular calcium increase and protein kinase C activation fail to initiate cell proliferation in the absence of a costimulatory signal. J Immunol 144:3701
32. 32. Norton SD, Zuckerman L, Urdahl KB, Shefner R, Miller J, Jenkins MK (1992) The CD28 ligand, B7, enhances IL-2 production by providing a costimulatory signal to T cells. J Immunol 149:1556
33. 33. Ogata S, Malmonis PJ, Itkowitz SH (1992) Mucins bearing the cancer-associated Sialosyl-Tn antigen mediated inhibition of natural killer cell cytotoxicity. Cancer Res 52:4741
34. + T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 42:1
35. 35. Regimbald LH, Pilarski LM, Longenecker BM, Reddish MA, Zimmermann G, Hugh JC (1996) The breast cancer mucin MUC1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res 56:4244
36. 36. Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, Gendler SJ (1998) Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res 58:315
37. 37. Schall TJ, O'Hehir RE, Goeddel DV, Lamb JR (1992) Uncoupling of cytokine mRNA expression and protein secretion during the induction phase of T cell anergy. J Immunol 148:381
38. 38. Schwartz RH (1992) Costimulation of T lymphocytes: the role of CD28, CTLA-4 and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71:1065
39. 39. Seregni S, Botti C, Massaron S, Lombardo C, Capobianco A, Bogni A, Bombardieri E (1997) Structure, function and gene expression of epithelial mucins. Tumori 83:625
40. 40. Sheer DG, Schlom J, Cooper HL (1998) Purification and composition of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B-72.3 Cancer Res 48:6811
41. + T cells by B7-transfected melanoma cells. Science 259:368
42. 42. Triozzi PL, Kim JA, Aldrich WA, Young D, Sampsel J, Martin EW (1994) Identification of tumor-reacting lymph node lymphocytes in vivo using radiolabeled monoclonal antibody. Cancer 73:580
43. 43. Tytgat KMAJ, Buller HA, Opdam FJM, Kim YS, Einerhand AW, Dekker J (1994) Biosynthesis of human colonic mucin: Muc2 is the prominent secretory mucin. Gastroenterology 107:1352
44. 44. Van de Wiel-van Kemenade E, Ligtenberg MJL, Boer AJ de, Buijs F, Vos HL, Melief CJM, Hilkens J, Figdor CG (1993) Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol 151:767
45. 45. Van Gool SW, Vandenberghe P, Boer M de, Ceuppens JL (1996) CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model. Immunol Rev 153:47
46. 46. Williams TM, Moolten DM, Makni H, Kim HW, Kant JA, Kamoun M (1992) CD28-stimulated IL-2 gene expression in Jurkat T cells occurs in part transcriptionally and is cylcosporine-A sensitive J Immunol 148:2609